BRAF and thyroid gland carcinoma: Since the approval of sorafenib, the new and more specific BRAF inhibitor dabrafenib has been assessed in clinical trials in radio-iodine refractory thyroid cancer, with lower incidence of adverse events and greater therapeutic outcomes23.